RECEIVED CENTRAL FAX CENTER

MAR 1 0 2006

PTO/SR/26 (09-04)
Approved for use through 07/31/2006. OMR 0651-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMD control number.

Docket Number (Optional) TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A "PRIOR" PATENT** 58289 (72021) Andrew Thurkauf et al. In re Application of: 10/647,191-Conf. #1037 Application No.: August 21, 2003 Filed: AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS Neurogen Corporation 100 percent interest in the The owner*, . of instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the 6,884,815 instant application which would extend beyond the expiration date of the full statutory term of prior patent No. as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner horeby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner doos not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; Is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims conceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the fike so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of regord. Reg. No. March 10, 2006 Signature Date John B. Alexander, Ph.D. Typed or printed name (617) 439-4444 Telephone Number Terminal discloimer fee under 37 CFR 1.20(d) is included. "Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.